1. Introduction
1.1 Executive Summary
1.2 Market Definition
1.3 Scope of the Study
2. Research Methodology
2.1 Secondary Research
2.2 Primary Research
2.3 Analytic Tools and Model
2.4 Economic Indicator
2.4.1 Base Year, Base Currency, Forecasting Period
2.5 Expert Validation
2.6 Study Timeline
3. Market Analysis
3.1 Industry Value Chain Analysis
3.2 Porter's Five Force Analysis
3.2.1 Bargaining Power of Buyers
3.2.2 Bargaining Power of Suppliers
3.2.3 Threats of Substitutes
3.2.4 Threats of New Entrants
3.2.5 Industry Rivalry
3.3 PESTLE Analysis
3.3.1 Political
3.3.2 Economical
3.3.3 Social
3.3.4 Technological
3.3.5 Legal
3.3.6 Environmental
3.4 SWOT Analysis
3.4.1 Strengths
3.4.2 Weakness
3.4.3 Opportunities
3.4.4 Threats
3.5 Y-O-Y Analysis
4. Market Dynamics
4.1. Drivers
4.1.1. Growing demand & higher acceptability for innovative therapies
4.1.2. Loss of patent exclusivity of the leading biologics drugs
4.1.3. Increasing capital investment from critical players
4.1.4. Rising prevalence of chronic diseases
4.2. Restraints & Challenges:
4.2.1. Stringent regulatory process & Initial high capital investment
4.2.2. Rising control & cost for accessing biologics
4.3. Opportunities
4.3.1. Technology advancements & drug innovations
5. APAC Biologics Market - By Product
5.1. Introduction
5.2. Monoclonal Antibodies
5.3. Vaccines
5.4. Recombinant harmonies/proteins
5.5. Cell Therapy
5.6. Gene Therapy
5.7. Others
6. APAC Biologics Market – By Applications
6.1. Introduction
6.2. Cancer
6.3. Infectious Diseases
6.4. Rare Diseases
6.5. Autoimmune Diseases
6.6. Others
7. APAC Biologics Market - By Geography
7.1. Introduction
7.2. APAC
7.2.1. China
7.2.2. Japan
7.2.3. India
7.2.4. Australia & New Zealand
7.2.3. Rest of APAC
8. Company Profiles
8.1. AbbVie Inc.
8.1.1. Company Overview
8.1.2. Business Segments
8.1.3. Financials (Public Companies)
8.1.4. Developments
8.1.5. SWOT Analysis (Public Companies)
8.2. Prana Biotechnologies
8.3. BTG PLC
8.4. Merck & Co
8.5. Novo Nordisk
8.6. Lonza Group
8.7. BioMarin Pharmaceutical
8.8. Pfizer Inc.
8.9. Astellas Pharma Inc.
8.10. Johnson & Johnson
8.11. Allergan plc
8.12. MJ Biopharm Pvt. Ltd.
8.13. AGC Biologics
9. Competitive Landscape
9.1. Market Share Analysis
9.2. Strategies Adopted by top companies
9.3. Mergers, Acquisitions, Collaborations & Agreements
10. Market Insights
10.1. Industry Experts Insights
10.2. Analysts Opinions
10.3. Investment Opportunities
11. Appendix
11.1 List of Tables
11.2 List of Figures